Zentalis Pharmaceuticals to Showcase Azenosertib Survival Data at ESMO 2026
Event summary
- Zentalis Pharmaceuticals will present overall survival data from the DENALI Part 1b study of azenosertib at ESMO Congress 2026.
- The rapid oral presentation is scheduled for October 23, 2026, highlighting long-term survival benefits in Cyclin E1-positive platinum-resistant ovarian cancer patients.
- ASPENOVA Phase 3 trial details will also be presented, comparing azenosertib to standard chemotherapy in this biomarker-selected population.
The big picture
Zentalis Pharmaceuticals is advancing its WEE1 inhibitor, azenosertib, as a potential first-in-class treatment for Cyclin E1-positive platinum-resistant ovarian cancer. The upcoming ESMO presentation underscores the strategic focus on biomarker-selected populations with high unmet medical needs, aligning with broader industry trends toward precision oncology and targeted therapies.
What we're watching
- Regulatory Pathway
- Whether the DENALI Part 2 data will support accelerated approval for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer.
- Clinical Trial Progress
- The pace at which ASPENOVA Phase 3 trial enrollment and results could position azenosertib for full approval.
- Market Differentiation
- How Zentalis can leverage the biomarker-driven approach to distinguish azenosertib in a competitive oncology landscape.
Related topics